Tepotinib is a first-generation targeted drug

Tepotinib is a targeted cancer drug that belongs to the third generation of MET inhibitors and is a tyrosine kinase inhibitor. It is also known as Tepmetko. This is a treatment for people who have non-small cell lung cancer (NSCLC) that has spread to other parts of the body (advanced cancer) and who have had previous treatment for NSCLC.

Tepotinib targets genetic changes found in some non-small cell lung cancers. This is a change in the mesenchymal-epithelial transition (MET) gene that causes cancer cells to produce an abnormal protein that causes the cells to grow uncontrollably. Tepotinib blocks abnormal proteins that slow or stop cancer growth. To make sure tepotinib is right for a patient, doctors will test samples of the patient's cancer cells to check for MET gene changes. Tepotinib comes as a tablet that patients can swallow whole without crushing or chewing it before swallowing. Tepotinib should also be taken with water and food or soon after a meal.

The original drug Tepotinib is already on the market in China, but it is not yet eligible for medical insurance. Tepotinib Original drug currently marketed overseas is relatively expensive, and the price of each box of 225mg*30 tablets may be around RMB 80,000 (the price may fluctuate due to exchange rates). There are already generic Tepotinib drugs produced in other countries. The ingredients of these generic drugs are basically the same as those of the original drug, but the price is relatively cheap. For example, the price of 225mg*60 tablets produced by a Laos pharmaceutical factory may be more than 8,000 yuan per box (the price may fluctuate due to exchange rates).